This study is currently recruiting participants.
Sponsor: Regeneron Pharmaceuticals
Information provided by: Rockefeller University
ClinicalTrials.gov Identifier: NCT01979016
Purpose: Dupilumab (also known as REGN668), a fully human monoclonal antibody, is directed against the IL-4 receptor alpha subunit (IL-4Rα), which is a component of IL-4 receptors Type I and Type II, as well as the IL-13 receptor system. The binding of dupilumab to IL-4Rα results in blockade of the function of both IL-4 and IL-13 signal transduction. The T cell-derived cytokines IL-4 and IL-13 play dominant roles in the induction and effector phases of inflammatory allergic diseases and are present in elevated levels in individuals with atopic diseases, including asthma and atopic dermatitis.
Name/Title of the Principal Investigator: Dr. Emma Guttman, MD/PhDContact Information: Saakshi Khattri, MD – Research Associate 1230 York Avenue New York, NY 10065 Business number: 212-327-8354/8333 Fax number: 212-327-8232 Recruitment Office 1-800-782-2737 email: email@example.com
For more information, please visit: http://clinicaltrials.gov/ct2/show/NCT01979016